Zug, Switzerland-based CRISPR Therapeutics AG said Tyler Dylan-Hyde retired as chief legal officer of the company.
Dylan-Hyde joined the company in January 2015.
The company develops gene-editing therapies for various diseases, including sickle cell disease and hemophilia.